Abstract:The overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway has been examined in various carcinomas and is reported to be significantly correlated with prognosis. However, little is known with regard to the PI3K/Akt signal transduction pathway in advanced non-small cell lung carcinoma (NSCLC). The present study investigated the expression of PI3K and phosphorylated (p)-Akt protein and its clinical significance in NSCLC. The clinical records of 157 patients with NSCLC (70 stage I-IIIA and 87 stage IIIB-IV cases), consisting of 75 cases of squamous cell carcinoma and 82 cases of adenocarcinoma, together with 30 resected lung cancer tumor-adjacent tissue samples, were retrospectively evaluated. PI3K and p-Akt expression in the NSCLC and tumor-adjacent tissues were measured using an immunohistochemical method, and its correlation with the clinicopathological data and prognosis in advanced NSCLC was evaluated. PI3K and p-Akt expression was significantly higher in the cancer tissues (chi(2)=14.8455; P=0.001) than in the tumor-adjacent tissues (chi(2)=14.2615; P=0.001). The overexpression of p-Akt in stage I-IIIA NSCLC was associated with lymph node metastasis (chi(2)=6.1189; P=0.013) and tumor-node-metastasis (TNM) stage (chi(2)=8.9752; P=0.011), however, no correlation was observed with gender, age, pathological type and histological grade. The overexpression of p-Akt in stage IIIB-IV NSCLC was only associated with TNM stage (chi(2)=5.7501; P=0.016), and no correlation was observed with gender, age, Pathological type, histological grade and Eastern Cooperative Oncology Group (ECOG) performance status (PS). The overexpression of PI3K was not found to correlate with the aforementioned clinicopathological variables in all patients. Survival was significantly improved in advanced NSCLC with PI3K- and p-Akt-negative expression compared with PI3K- and p-Akt-positive expression [P13K: 17.70 months (95% confidence interval (CI), 15.11-20.28 mont hs) vs. 13.43 months (95% CI, 11.83-15.02 months); P=0.004; and p-Akt: 17.13 months (95% CI, 14.93-19.34 months) vs. 13.07 months (95% CI, 11.32-14.82 months); P=0.007]. Multivariate analysis showed that PI3K [hazard ratio (HR)=2.143; 95% CI, 1.211-3.790; P=0.009], p-Akt (HR=1.991; 95% CI, 1.009-3.927; P=0.047), TNM stage (HR=4.788; 95% CI, 2.591-8.848; P=0.001) and ECOG-PS (HR=3.272; 95% CI, 1.701-6.296; P=0.001) were independent predictors for survival in stage IIIB-IV NSCLC. These results indicated that p-Akt overexpression closely correlates with factors of an unfavorable prognosis in NSCLC. PI3K and p-Akt overexpression are independent markers of a poor prognosis in advanced NSCLC.

Expression of Proline-Rich Akt-substrate PRAS40 in Cell Survival Pathway and Carcinogenesis

Targeting PRAS40: a novel therapeutic strategy for human diseases

Upregulation of Serine Metabolism Enzyme PSAT1 Predicts Poor Prognosis and Promotes Proliferation, Metastasis and Drug Resistance of Clear Cell Renal Cell Carcinoma.

Effect of PI3K/Akt Signaling Pathway on PRAS40Thr246 Phosphorylation in Gastric Cancer Cells

The Molecular Landscape and Biological Alterations Induced by PRAS40-Knockout in Head and Neck Squamous Cell Carcinoma

[Phophorylated Akt Protein Expression in Non-Small Cell Lung Cancer].

PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways

Pras40 Alleviates Neurotoxic Prion Peptide-Induced Apoptosis Via Mtor-Akt Signaling

Insulin-like Growth Factor-1 Induces the Phosphorylation of PRAS40 Via the PI3K/Akt Signaling Pathway in PC12 Cells.

PRPF40A As a Potential Diagnostic and Prognostic Marker is Upregulated in Pancreatic Cancer Tissues and Cell Lines: an Integrated Bioinformatics Data Analysis

Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation

PRAS40 Promotes NF-κB Transcriptional Activity Through Association with P65

Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma.

Targeting Cytosolic Phospholipase A2 Α in Colorectal Cancer Cells Inhibits Constitutively Activated Protein Kinase B (AKT) and Cell Proliferation

The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: a Meta-Analysis.

High Kpnβ1 Expression Promotes Non-Small Cell Lung Cancer Proliferation and Chemoresistance Via the PI3-kinase/AKT Pathway.

The PKA RIα/A‐kinase Anchoring Proteins 10 Signaling Pathway and the Prognosis of Colorectal Cancer

The Gene RAD51AP1 Promotes the Progression of Pancreatic Cancer Via the PI3K/Akt/NF-κB Signaling Pathway.

Effects of PRPS2 on lung cancer cell proliferation, tumor growth in vitro, and tumorigenic ability in vivo

Ott_a_206039 5037..5051